2024-09-04T17:22:43+00:00 2023-12-31 440160260 Forvis Mazars LLP 135 West 50th Street New York NY 10020 990 2023-01-01 362883000 American Liver Foundation AMER 2126681000 PO Box 229 West Orange NJ 07052 David Ticker CFO 2126681000 2024-09-04 true Aaron Shapiro P01333816 2128674000 2024-09-04 2023 2024-08-08 14:25:15Z DAVID TICKER PO Box 229 West Orange NJ 07052 8093217 false X WWW.LIVERFOUNDATION.ORG X 1976 IL OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. 22 22 37 1500 0 0 5799860 4896417 0 95740 246747 -102758 -135250 5792842 5007914 400000 0 3077864 3344576 20000 619263 1178221 1310034 4256085 5074610 1536757 -66696 8657364 9547099 997283 1651882 7660081 7895217 X OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. false false 1028249 SEE SCHEDULE O 996147 SEE SCHEDULE O 767649 SEE SCHEDULE O 582056 400000 RESEARCH: AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. 493265 AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. 1075321 400000 3867366 true true false false false false false true true true false false false true false true false false false false false false true true false false true true true false false false false false false false false false false false false false false false false false true 50 0 true 37 true false false false false false true true false false false true false false false X 22 22 false false false false false false false true true false false true true true true true true true true false AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X DAVID TICKER 2126681000 PO BOX 229 WEST ORANGE NJ 07052 CARLO FRAPPOLLI SECRETARY 0.3 X X 0 0 0 EMMANUEL THOMAS MD PHD BOARD CHAIR 0.3 X X 0 0 0 GENE CAUTILLO TREASURER 0.3 X X 0 0 0 ALLAN DOERR BOARD MEMBER 0.3 X 0 0 0 ANNE DOYEN BOARD MEMBER 0.3 X 0 0 0 CONNIE DENEWETH BOARD MEMBER 0.3 X 0 0 0 DAN WEIL BOARD MEMBER 0.3 X 0 0 0 DAVID FRANK BOARD MEMBER 0.3 X 0 0 0 ELLEN RUCKER-SELLERS BOARD MEMBER 0.3 X 0 0 0 HILLEL TOBIAS MD PHD BOARD MEMBER 0.3 X 0 0 0 KEVIN LEE BOARD MEMBER 0.3 X 0 0 0 LIZ LEESMAN BOARD MEMBER 0.3 X 0 0 0 MICHAEL KERR BOARD MEMBER 0.3 X 0 0 0 MIKE BRAUNSTEIN BOARD MEMBER 0.3 X 0 0 0 NICK DEROMA BOARD MEMBER 0.3 X 0 0 0 NICOLE SMITH PHD BOARD MEMBER 0.3 X 0 0 0 PETER CULLEN BOARD MEMBER 0.3 X 0 0 0 RICHARD MILLER BOARD MEMBER 0.3 X 0 0 0 ROCKY YAPP MD MPH AGAF BOARD MEMBER 0.3 X 0 0 0 ROTONYA CARR MD BOARD MEMBER 0.3 X 0 0 0 THOMAS NEALON BOARD MEMBER 0.3 X 0 0 0 UDEME EKONG BOARD MEMBER 0.3 X 0 0 0 DAVID TICKER CFO 35.0 X 204878 0 24383 LORRAINE STIEHL CEO 35.0 X 197042 0 25885 JULIANN KIMBROUGH CHIEF MKTG, COMMS, PUBLIC AFF. 35.0 X 187646 0 6503 ABBY AMANKWAA CONTROLLER 35.0 X 135350 0 8085 HEIDI DANIELS VP OF DEVELOPMENT 35.0 X 161376 0 25270 JACKIE DOMINGUEZ NATL SR. DIRECTOR, ENGAGEMENT 35.0 X 126388 0 4404 KELLY SMITH VP OF EVENTS 35.0 X 160040 0 39045 SHERI SINGER NATL DIRECTOR, DEV./ENGAGEMENT 35.0 X 131950 0 708 1304670 0 134283 10 false true false Amplotech LLC PO Box 16422 San Juan PR 00908 Web Master & Marketing Support 189690 1 24774 2077476 2794167 4896417 0 0 0 0 0 249077 249077 0 0 2759466 2761796 -2330 0 -2330 -2330 159602 2077476 323507 -163905 -163905 OTHER 900099 28655 28655 0 0 0 0 28655 5007914 0 0 111497 225000 225000 175000 175000 646338 497587 75046 73705 2252541 1734135 261539 256867 48328 37206 5611 5511 165145 127138 19175 18832 232224 178779 26963 26482 53389 41468 3419 8502 53354 41440 3417 8497 20000 20000 14679 14679 457985 371255 30612 56118 38483 27508 78 10897 238210 81427 112625 44158 66020 52207 6969 6844 43476 33503 5032 4941 102692 87074 5572 10046 2608 2608 13702 10548 1592 1562 33023 25423 3834 3766 HOTEL AND CATERING 66931 28104 1 38826 MISCELLANEOUS 125482 92564 9209 23709 0 0 0 0 5074610 3867366 587981 619263 2416178 1943664 30595 813057 171067 241647 0 0 0 0 77410 135054 67468 18479 25523 48989 5936591 6223346 0 0 0 141342 8657364 9547099 150360 178903 18750 400000 166115 267500 662058 660578 0 0 0 144901 997283 1651882 5591473 5136293 2068608 2758924 7660081 7895217 8657364 9547099 -66696 301832 0 X false true X true false X 8927298 5317288 6782864 5799860 4896417 31723727 0 0 8927298 5317288 6782864 5799860 4896417 31723727 2564698 29159029 73774 45040 54832 92900 249077 515623 0 35890 184297 113635 49115 28655 411592 32650942 0 0.8931 0.8749 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER, COLUMN A - 35890.0, COLUMN B - 184297.0, COLUMN C - 113635.0, COLUMN D - 49115.0, COLUMN E - 28655.0, COLUMN F - 411592.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true X 943717 189335 150000 983052 1152635 -208918 943717 988115 164520 1152635 1222206 95449 329540 988115 1112588 222118 112500 1222206 0.0 0.7548 0.2452 false false 44968 18479 26489 22500 22500 48989 Lease Liability 144901 144901 5348456 301832 53389 0 355221 4993235 14679 0 14679 5007914 5113320 53389 0 53389 5059931 14679 0 14679 5074610 Schedule D, Part X, Line 2 ASC 740 Footnote MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. Schedule D, Part IV, Line 2b Explanation of escrow agreement FUNDS HELD ON BEHALF OF OTHERS - ALF ACTS AS AN ADMINISTRATOR FOR FUNDS COLLECTED ON BEHALF OF LIVER TRANSPLANT PATIENTS. ALF DISBURSES FUNDS TO COVER THE COST OF PROPERLY DOCUMENTED POST-SURGERY EXPENSES. Schedule D, Part V, Line 4 Intended uses of endowment funds THE INTENDED USE OF ENDOWMENT FUNDS HAS BEEN SPECIFIED BY THE DONOR. ALL FUNDS ON HAND ARE USED TO GENERATE INTEREST/DIVIDEND INCOME AND CAPITAL GAINS TO SUPPORT VARIOUS RESEARCH INITIATIVES. X X X X X true Brightdot LLC 3434 Edwards Mill Road Suite 112-14 3 Raleigh NC 27612 Major Gift Cultivation false 0 20000 -20000 0 20000 -20000 CA CO CT DE DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ PR RI SC SD TN TX UT VT VA AR WA WV WI WY Gala 670743 509643 161100 0 296 30082 95500 7252 3000 Boston Marathon 620726 620726 0 0 3337 15230 26357 1078 14250 18 945609 947107 -1498 0 27210 54445 2725 16675 26070 2237078 2077476 159602 0 30843 99757 124582 25005 43320 323507 -163905 true The University of Toledo 2801 West Bancroft Street Toledo OH 43606 346401483 501(c)(3) 75000 Liver Disease Research Children's Hospital Medical Center 3333 Burnet Ave MLC 4900 Cincinnati OH 45229 310833936 501(c)(3) 75000 Liver Disease Research New York University LISOM Grants 550 First Avenue New York NY 10016 135562308 501(c)(3) 75000 Liver Disease Research 3 0 Post Doctoral Award 7 175000 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. Award recipients are required to submit annual progress updates and fiscal officers are required to sign off that grant funds were used in accordance with grant terms. X X false false false false false false false false false DAVID TICKER CFO 194878 0 10000 0 0 0 5928 0 18455 0 229261 0 0 0 LORRAINE STIEHL CEO 197042 0 0 0 0 0 6000 0 19885 0 222927 0 0 0 JULIANN KIMBROUGH CHIEF MKTG, COMMS, PUBLIC AFF. 177646 0 10000 0 0 0 5250 0 1253 0 194149 0 0 0 KELLY SMITH VP OF EVENTS 150040 0 10000 0 0 0 4680 0 34365 0 199085 0 0 0 HEIDI DANIELS VP OF DEVELOPMENT 161376 0 0 0 0 0 4944 0 20326 0 186646 0 0 0 Form 990, Part III, Line 4a PUBLIC AND PATIENT EDUCATION: AS PART OF OUR THINK LIVER THINK LIFE INITIATIVE, ALF MADE GREAT STRIDES IN RAISING AWARENESS ABOUT FATTY LIVER DISEASE AND SCREENING AT-RISK INDIVIDUALS FOR FATTY LIVER. WE CREATED AN ONLINE QUIZ TO HELP PEOPLE UNDERSTAND IF THEY ARE AT RISK FOR FATTY LIVER DISEASE. AS OF DECEMBER 2023, 7,500 PEOPLE HAD TAKEN THE QUIZ AND 90% HAD SHOWN RISK FACTORS FOR FATTY LIVER DISEASE. WE DEVELOPED NEARLY 50 NEW PARTNERSHIPS WITH FEDERALLY QUALIFIED HEALTH CENTERS (FQHCS) AND COMMUNITY CLINICS TO CONDUCT FATTY LIVER TESTING. TO DATE, 1,204 PEOPLE PARTICIPATED IN SCREENINGS TO TEST FOR THE PREVALENCE OF FATTY LIVER DISEASE. OF THOSE TESTED, 60% HAVE A SCORE OF S1 OR HIGHER AND 33% HAVE AN S2 OR HIGHER (WHICH MEANS THAT THE DISEASE IS PRESENT). THIS DATA SHOWS WE HAVE BEEN SUCCESSFUL IN TARGETING INDIVIDUALS WHO HAVE UNDIAGNOSED LIVER DISEASE AND CONNECTING THEM TO CARE. ALF HOSTED AN AUTOIMMUNE LIVER DISEASE FORUM. THERE WERE 400 REGISTRANTS AND OVER 180 ATTENDEES AT THE EVENT. THIS FORUM BROUGHT TOGETHER PATIENTS, CAREGIVERS, HEPATOLOGISTS, PRIMARY CARE PROVIDERS, PATIENT ADVOCACY ORGANIZATION PERSONNEL, AND INDUSTRY REPRESENTATIVES. A PATIENT BILL OF RIGHTS, EXECUTIVE SUMMARY AND PATIENT TOOLKIT WILL BE CREATED AND PUBLISHED AFTER THE EVENT. ALF'S PEDIATRIC LIVER DISEASE INFORMATION CENTER WAS LAUNCHED ON FEBRUARY 28, 2023. THESE ONLINE RESOURCES FEATURE DISEASE-SPECIFIC INFORMATION, PATIENT STORIES, VIDEOS, AND EDUCATIONAL RESOURCES. HTTPS://LIVERFOUNDATION.ORG/LIVERDISEASES/ PEDIATRIC-LIVER-INFORMATION-CENTER/ ON FEBRUARY 28TH, RARE DISEASE DAY, WE RELEASED THE OFFICIAL RARE LIVER DISEASE PATIENT BILL OF RIGHTS AND EXECUTIVE SUMMARY FROM THE 2022 RARE LIVER DISEASE SUMMIT. THE PATIENT BILL OF RIGHTS ENCOURAGES RARE DISEASE PATIENTS TO ADVOCATE FOR THEMSELVES AND PROMOTE A BETTER WORKING RELATIONSHIP WITH THE MEMBERS OF THEIR HEALTHCARE TEAM. ALF SUPPORTED THE CDC'S DIVISION OF VIRAL HEPATITIS IN LAUNCHING THEIR PILOT COLLECTION PROCESS. WHERE THE CDC WILL BE CONDUCTING INTERVIEWS WITH CURRENT AND FORMER HEPATITIS C PATIENTS TO COLLECT TESTIMONIALS THAT CAN BRING AWARENESS TO WHAT HELPS AND/OR PREVENTS PATIENTS FROM RECEIVING HEPATITIS C TREATMENT. ALF SHARED BEST PRACTICES FOR DEVELOPING PATIENT STORIES AND RECRUITING PARTICIPANTS. ALF WILL CONTINUE TO SUPPORT THE CDC WHEN THIS PROJECT IS APPROVED. ALF HAS PARTNERED WITH PLATFORM Q ON A PROGRAM ENTITLED, "OVERCOMING STIGMA AND ADVOCATING FOR EQUITABLE CARE IN LIVER CANCER." A PANEL OF LIVER CANCER SPECIALISTS FROM MEMORIAL SLOAN KETTERING PROVIDED INFORMATION ON NEW AND EMERGING TREATMENTS FOR LIVER CANCER. IN MAY, ALF HOSTED A HEPATITIS C WEBINAR IN COLLABORATION WITH THE CENTERS FOR DISEASE CONTROL AND PREVENTION DIVISION OF VIRAL HEPATITIS. WE HAD 695 PEOPLE REGISTERED AND 172 LIVE ATTENDEES. THIS WEBINAR PROVIDES INFORMATION ABOUT THE CDC VITAL SIGNS REPORT ON NEWLY-REPORTED CASES OF HEPATITIS C AND UPDATED HEPATITIS C SCREENING RECOMMENDATIONS, HOW TO PARTNER TO INCREASE HEPATITIS C TREATMENT AND CDC CANCER CONTROL PROGRAMS. THE AMERICAN LIVER FOUNDATION HOSTED A TWO-DAY END-STAGE LIVER DISEASE ROUNDTABLE TO DISCUSS ISSUES RELATED TO END STAGE LIVER DISEASE. THIS MEETING WILL FOCUS ON TOPICS SUCH AS COMPLICATIONS OF END-STAGE LIVER DISEASE, SUPPORT FOR PATIENTS AND CAREGIVERS, AND GAPS IN RESEARCH FOR END-STAGE LIVER DISEASE. LIVER HEALTH TODAY, ALF'S MONTHLY E-NEWSLETTER FOR PATIENTS AND CAREGIVERS, WAS DISTRIBUTED MONTHLY TO 225,000 PATIENTS, SUPPORTERS, AND VOLUNTEERS IN 2023. THE 2023 LIVER CANCER CONFERENCE WAS PRESENTED VIRTUALLY TO 272 ATTENDEES, AND THE RECORDING OF THE CONFERENCE AND ITS SESSIONS HAS BEEN VIEWED 785 AND 1,109 TIMES, RESPECTIVELY. ALF UPDATED AND CREATED NEW WEB CONTENT ON A VARIETY OF LIVER DISEASE TOPICS. THE WEBSITE WAS VISITED BY ALMOST 2.3 MILLION PEOPLE IN 2023. Form 990, Part III, Line 4b PATIENT SUPPORT: THESE THREE AREAS OF WORK HAVE RESULTED IN FULFILLMENT OF MISSION-RELATED GOALS IN 2023. RESPONDED TO 3,625 HELPLINE CALLS, LIVE CHATS AND EMAILS FROM PATIENTS, CAREGIVERS AND THE PUBLIC. HOSTED FACEBOOK SUPPORT GROUPS FOR PEOPLE WITH PRIMARY BILIARY CHOLANGITIS, LIVER CANCER, NASH, AND PEDIATRIC LIVER DISEASES. IN 2023, THE CUMULATIVE TOTAL OF PARTICIPATING FACEBOOK SUPPORT GROUP MEMBERS WAS 8,909. INITIATED PLANNING AND DEVELOPMENT OF ITS "SHARING THE JOURNEY" SERIES OF VIRTUAL SUPPORT GROUPS FOR PATIENTS, CAREGIVERS, AND LIVER TRANSPLANT RECIPIENTS FOR LAUNCH IN MARCH 2024. BEGAN LAYING THE GROUNDWORK FOR ITS "CARING CONNECTIONS" PEER-TO-PEER MENTORING PROGRAM, WHICHWILL LAUNCH IN THE SUMMER OF 2024. PRESENTED PEDIATRIC LIVER DISEASE WEBINARS AND DEVELOPED A TOOLKIT FOR PARENTS OF CHILDREN DIAGNOSED WITH LIVER DISEASE, SPECIFICALLY BILIARY ATRESIA. IDENTIFIED MEDICAL PROFESSIONALS TO SERVE AS AN EDUCATIONAL PROVIDER FOR VETERAN AFFAIRS AND MODERATOR OF ALF'S PBC FACEBOOK SUPPORT GROUP. RECRUITED NEW ORGANIZATIONAL PARTNERS THAT SERVE THE HISPANIC COMMUNITY AND ASSISTED WITH THE TRANSLATION OF ALF PRINT MATERIALS FROM ENGLISH TO SPANISH. Form 990, Part III, Line 4c COMMUNITY SERVICE: ALF CONDUCTS ADVOCACY WORK ON BEHALF OF THE PATIENT COMMUNITY THROUGHOUT THE YEAR, ACTIVELY RAISING AWARENESS OF PERTINENT LEGISLATION AFFECTING THE LIVER COMMUNITY AMONG THE FEDERAL GOVERNMENT. PARTNERED WITH 2,356 PATIENT ADVOCATES WHO FURTHER ALF'S MISSION THROUGH NATIONAL LEGISLATIVE CALLS TO ACTION AND SENDING LETTERS TO THEIR CONGRESS MEMBERS. PRIORITIES INCLUDED: *PROGRAMMATIC FUNDING OF $1.5M TO FUND A STUDY ON NONALCOHOLIC FATTY LIVER DISEASE THROUGH THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE. THIS FUNDING, THE FIRST OF ITS KIND, WAS APPROVED IN THE 2025 FEDERAL BUDGET. *ENSURING THAT LANGUAGE FOR AN APPROPRIATIONS BILL FOR A STUDY ON NAFLD IS INCLUDED IN THE FINAL FUNDING BILL FOR FISCAL YEAR 2024 *PLANNING A CAPITOL HILL BRIEFING FOR JANUARY 2024 ENTITLED, OBESITY: THE LEADING CAUSE OF NONALCOHOLIC FATTY LIVER DISEASE AND THE MOST URGENT THREAT TO PUBLIC HEALTH TODAY. THIS BRIEFING WILL FEATURE MEDICAL PROFESSIONALS AND PATIENT ADVOCATES TO DISCUSS CURRENT DYNAMICS AROUND OBESITY AND LIVER DISEASE. *ADVOCATES ASKED THAT MEMBERS SUPPORT THE FOLLOWING LEGISLATION LIVING DONOR PROTECTION ACT (S. 377/H.R. 1255), THE SAFE STEP ACT (S. 464/H.R. 2163), THE LIVER ACT (S. 3041/H.R. 5675), AND THE HELP COPAYS ACT (H.R. 5801) PLUS FUNDING REQUESTS FOR NIH, ARPAH, CDC, AND HRSA. Form 990, Part III, Line 4d Description of other program services (Expenses $ 582,056 including grants of $ 400,000) RESEARCH: AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. Form 990, Part III, Line 4d Description of other program services (Expenses $ 493,265 including grants of $) AMERICAN LIVER FOUNDATION (ALF) HAS A HISTORY OF COMMITMENT TO RESEARCH FUNDING DATING BACK TO 1979, BUT IN 2023 (AFTER A COVID-RELATED HIATUS) IT ESTABLISHED A DEDICATED RESEARCH DEPARTMENT THAT WILL BUILD A SOLID FOUNDATION TO GROW THE RESEARCH PROGRAM OVER THE NEXT FEW YEARS. PRIORITIES WILL INCLUDE MAKING AN IMPACT ON SERIOUS CHALLENGES SUCH AS INADEQUATE FUNDING LEVELS FOR LIVER RESEARCH AND A SCARCITY OF RESEARCHERS DEVOTED TO THE LIVER FIELD. THIS COMMITMENT WILL RESULT IN IMPROVEMENTS IN THERAPEUTIC OPTIONS AND CLINICAL OUTCOMES FOR PATIENTS. KEY ACCOMPLISHMENTS INCLUDED: *CONDUCTED THE ALF RESEARCH AWARDS PROGRAM, WHICH GARNERED A RECORD 21 LIVER SCHOLAR AND 41 POSTDOCTORAL RESEARCH FELLOWSHIP APPLICATIONS. FURTHER, A NEWLY CONSTITUTED GRANTS REVIEW COMMITTEE REVIEWED THE APPLICATIONS FOR LIVER SCHOLAR AWARDS AND POSTDOCTORAL RESEARCH FELLOWSHIP AWARDS, WHICH WERE AWARDED IN DECEMBER 2023. ALF AWARDED 3 LIVER SCHOLAR AWARDS AND 7 POST-DOCTORAL AWARDS TOTALING $400,000 IN FUNDING. *DEVELOPED A PATIENT REGISTRY THAT WILL BE PROMOTED AMONG ACADEMIC AND INDUSTRY PARTNERS TO HELP IDENTIFY RESEARCH TOPICS AND RECRUIT FOR CLINICAL TRIALS. *PARTICIPATED IN THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASE'S LIVER MEETING. RESEARCH STAFF PREPARED AND PRESENTED A POSTER ABOUT THE PILOT PROGRAM FOR ALF'S SIGNATURE LIVER SCREENING PROGRAM, THINK LIVER THINK LIFE. AS PART OF ALF'S MISSION TO EDUCATE PATIENTS, STAFF ATTENDED SESSIONS AND SUMMARIZED CONTENT FROM THE LIVER MEETING FOR DISTRIBUTION TO ALF'S PATIENT CONSTITUENTS. Form 990, Part VI, Line 11b Review of form 990 by governing body A DRAFT OF THE FORM 990 IS SENT TO THE FINANCE COMMITTEE FOR REVIEW AND COMMENTS IN THE MONTHLY MEETING PRIOR TO FILING. IN ADDITION, A DRAFT OF THE FORM 990 IS ALSO SENT TO EACH BOARD MEMBER FOR DISCUSSION. AFTER QUESTIONS AND COMMENTS ARE ADDRESSED AND THE FORM 990 IS APPROVED, IT IS READY FOR FILING. Form 990, Part VI, Line 12c Conflict of interest policy ANNUALLY, OUR CONFLICT OF INTEREST FORM IS COMPLETED BY OFFICERS AND DIRECTORS. THE FORM MUST INDICATE ANY POSSIBLE CONFLICTS OF INTEREST AND BE SIGNED BY ALL OFFICERS AND DIRECTORS. WHEN ANY SUCH CONFLICT OF INTEREST IS RELEVANT TO A MATTER REQUIRING ACTION BY THE BOARD, THE INTERESTED PERSON SHALL CALL IT TO THE ATTENTION OF THE BOARD AND SUCH PERSON SHALL NOT VOTE ON THE MATTER. MOREOVER, THE PERSON HAVING A CONFLICT SHALL RETIRE FROM THE ROOM IN WHICH THE BOARD IS MEETING AND SHALL NOT PARTICIPATE IN THE FINAL DELIBERATION OR DECISION REGARDING THE MATTER UNDER CONSIDERATION. HOWEVER, THAT PERSON SHALL PROVIDE THE BOARD WITH ANY AND ALL RELEVANT INFORMATION. THE MINUTES OF THE MEETING OF THE BOARD, SHALL REFLECT THAT THE CONFLICT OF INTEREST WAS DISCLOSED AND THAT THE INTERESTED PERSON WAS NOT PRESENT DURING THE FINAL DISCUSSION OR VOTE AND DID NOT VOTE. WHEN THERE IS A DOUBT AS TO WHETHER A CONFLICT OF INTEREST EXISTS, THE MATTER SHALL BE RESOLVED BY A VOTE OF THE BOARD. Form 990, Part VI, Line 15a Process to establish compensation of top management official CEO COMPENSATION IS DETERMINED BY THE NATIONAL BOARD OF DIRECTOR'S EXECUTIVE COMMITTEE AND APPROVED BY THE BOARD MEMBERS. IN DETERMINING SALARY LEVELS, THE EXECUTIVE COMMITTEE REVIEWS AN ANNUAL SALARY SURVEY OF NATIONAL VOLUNTARY HEALTH ORGANIZATIONS PREPARED FOR THE NATIONAL HEALTH COUNCIL AND REVIEWS PRIOR YEAR PERFORMANCE. CURRENT MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION ARE ALSO CONSIDERED IN SETTING COMPENSATION. THIS REVIEW WAS LAST CONDUCTED IN 2023. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE SALARY OF OFFICERS AND KEY EMPLOYEES ARE DETERMINED BY THE CEO AND CFO BASED ON PERFORMANCE, MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION. Form 990, Part VI, Line 19 Required documents available to the public THE ANNUAL AUDIT REPORT AND FORM 990 ARE AVAILABLE VIA WWW.LIVERFOUNDATION.ORG AND FORM 1023 AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST.